These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 20207566)
21. Disease management. Getting out from under drug companies' shadows. Heimoff S Manag Care; 2000 Mar; 9(3):39-40, 42-3. PubMed ID: 11066212 [No Abstract] [Full Text] [Related]
22. Payer and Pharmaceutical Manufacturer Considerations for Outcomes-Based Agreements in the United States. Brown JD; Sheer R; Pasquale M; Sudharshan L; Axelsen K; Subedi P; Wiederkehr D; Brownfield F; Kamal-Bahl S Value Health; 2018 Jan; 21(1):33-40. PubMed ID: 29304938 [TBL] [Abstract][Full Text] [Related]
23. Examining Misaligned Incentives for Payers and Manufacturers in Value-Based Pharmaceutical Contracts. Kannarkat JT; Good CB; Kelly E; Parekh N J Manag Care Spec Pharm; 2020 Jan; 26(1):63-66. PubMed ID: 31880231 [TBL] [Abstract][Full Text] [Related]
24. How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? - the good, the bad, and the ugly ways. Inotai A; Kaló Z Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):627-632. PubMed ID: 31810392 [No Abstract] [Full Text] [Related]
25. The economics of licensing contracts. Mason R; Savva N; Scholtes S Nat Biotechnol; 2008 Aug; 26(8):855-7. PubMed ID: 18700253 [No Abstract] [Full Text] [Related]
26. How to avoid the dangers of disease-specific carve-outs. Capitation Manag Rep; 2000 Aug; 7(8):126-7. PubMed ID: 11186760 [No Abstract] [Full Text] [Related]
27. Precipitating factors for pharmaceutical firms. McCarthy R State Health Care Am; 1997; ():39-43. PubMed ID: 10168083 [No Abstract] [Full Text] [Related]
28. Designing the financial tools to promote universal access to AIDS care. Leoni P; Luchini S J Health Econ; 2011 Jan; 30(1):181-8. PubMed ID: 21126788 [TBL] [Abstract][Full Text] [Related]
29. Value-Based Pharmaceutical Contracts: Value for Whom? Kannarkat JT; Good CB; Parekh N Value Health; 2020 Feb; 23(2):154-156. PubMed ID: 32113619 [TBL] [Abstract][Full Text] [Related]
30. [Economic assessment on medications: effects on pharmaceutical industry and health administration]. Badía X; Sacristán JA Rev Sanid Hig Publica (Madr); 1995; 69(1):17-27. PubMed ID: 7644878 [TBL] [Abstract][Full Text] [Related]
33. The new drug war. Parloff R Fortune; 2004 Mar; 149(5):144-6, 148, 150 passim. PubMed ID: 15015428 [No Abstract] [Full Text] [Related]
34. Industry perspectives: ensuring vaccination of children and adolescents without financial barriers. Feinberg MB; Gordon L Pediatrics; 2009 Dec; 124 Suppl 5():S563-4. PubMed ID: 19948589 [No Abstract] [Full Text] [Related]
35. Health maintenance organizations and the rationing of medical care. Luft HS Milbank Mem Fund Q Health Soc; 1982; 60(2):268-306. PubMed ID: 6919772 [No Abstract] [Full Text] [Related]